About Oncimmune
Oncimmune is a Healthcare company based in Nottingham (United Kingdom) founded in 2006 by Geoffrey Hamilton Fairley, and was acquired by Freenome in May 2023. Diagnostics and risk assessment solutions for lung cancer are developed. It operates on a Professional Services and Data-as-a-Service model. Oncimmune has completed 1 acquisition, including Protagen. Its chief executive, as recorded, is Geoffrey Hamilton Fairley. Oncimmune offers products and services including ImmunoINSIGHTSâ„¢, Targeted Panels & Arrays, and Bioinformatics & Data Science. Its focus areas include Biotechnology and Biomarker Discovery. Its legal entity is Alden Scientific Holdings Incorporated. Its competitors include Oxford Cancer Analytics and Inivata; 2 of its 2 listed competitors have raised funding.
Company details
Oncimmune is engaged in the development of advanced antibody biomarker discovery platforms, primarily through its proprietary ImmunoINSIGHTS engine. The company operates in the healthcare and biotechnology sectors, offering solutions for precision medicine across areas such as immuno-oncology, autoimmune diseases, and infectious diseases. Services include targeted panels, arrays, and bioinformatics for data integration. With a vast antigen library and cutting-edge technology, Oncimmune collaborates with clients to provide insights into the immune system for improved diagnostics and treatments.
- Headquarters Nottingham, United Kingdom
- Founders Geoffrey Hamilton Fairley
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website oncimmune.com
- Social LinkedIn X Facebook YouTube
- Acquired by Freenome (May 2023)
- Legal Name Alden Scientific Holdings Incorporated
- Latest Funding Round$2.87M (USD), Post-IPO
Oct 2024
- InvestorsFreenome Health
& 4 more
- Investments & Acquisitions
- Acquired byFreenome
(May 2023)
Products & Services of Oncimmune
Oncimmune offers a comprehensive portfolio of products and services, including ImmunoINSIGHTS™, Targeted Panels & Arrays, and Bioinformatics & Data Science.
Platform used for antibody biomarker discovery and analysis.
Services offered for customized biomarker panel development.
Analytics provided for biomarker data integration and insights.
Apps and channels of Oncimmune
its YouTube channel Oncimmune has 124 subscribers and 6 videos.
Videos from Oncimmune
The most watched videos on Oncimmune's YouTube channel, Oncimmune (124 subscribers). Click a video to play it here.
More on Oncimmune.
Funding Insights of Oncimmune
- Total Rounds 17
- Last Round Post-IPO — $2.87M
- First Round $150,153
(May 2011)
- Investors Count 4
Latest 10 of 17 funding rounds of Oncimmune with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2024 | $2.87M | Post-IPO | – | – | – |
| Dec 2022 | Post-IPO | – | – | – | |
| Mar 2021 | $12.34M | Post-IPO | – | – | – |
| Oct 2020 | Grant | – | – | ||
| Jun 2020 | $396,664 | Grant | – | – | |
| Apr 2020 | $2.34M | Grant | – | – | |
| Sep 2019 | $9.39M | Debt – Conventional | – | – | |
| Sep 2019 | $2.9M | Grant | – | – | |
| Sep 2019 | $211,441 | Grant | – | – | |
| Sep 2018 | $985,225 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Oncimmune
Oncimmune has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Freenome Health, HHS and UK Research and Innovation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Alternative financing is provided by IPF Partners for healthcare. | ipfpartners.com | Luxembourg, Luxembourg | ||
Research and innovation funding is managed for UK advancement. | 2018 | ukri.org | Swindon, United Kingdom | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Offers personalized cancer testing, monitors treatment effectiveness, and tracks cancer status closely. | 2010 | genostics.com.au | Sydney, Australia | |
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | freenome.com | United States |
Investor details for Oncimmune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Oncimmune
1 people are tracked at Oncimmune (1 in leadership).
| Name | Role | Group |
|---|---|---|
Geoffrey Hamilton Fairley | Founder & CEO | Leadership |
Complete people profiles for Oncimmune
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Oncimmune
Oncimmune has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Protagen.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Autoantibody biomarkers are utilized for autoimmune disease diagnostics. | protagen.com | Dortmund, Germany | 1997 | Mar 2019 | •••• |
Complete acquisition details for Oncimmune
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Oncimmune
6 dated milestones of Oncimmune across 18 years, from founding to its latest funding, stage changes and deals.
Competitors of Oncimmune
Oncimmune has 2 listed competitors in our database, 2 of them funded. They include Oxford Cancer Analytics and Inivata.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| oxcan.org | 2018 | Oxford, United Kingdom | $16.47M | 7 | Provider of a platform for detection of lung cancer | |
| inivata.com | 2014 | Cambridge, United Kingdom | $188.79M | 81 | Liquid biopsy platform for cancer detection is developed. |
Detailed competitors of Oncimmune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Oncimmune
The website of Oncimmune (oncimmune.com) receives about 2.3K visits a month and ranks #9,834,746 among all websites worldwide, #7,784 in Biotechnology and Pharmaceuticals.
- Monthly visits2.3K
▲ 41.2% vs previous month
- Global rank#9,834,746
among all websites
- Category rank#7,784
Health · Biotechnology and Pharmaceuticals
- Bounce rate47%
- Pages per visit1.6
- Average visit20 sec
- DevicesDesktop 22% · Mobile 78%
Websites whose visitors overlap most with Oncimmune. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
airliewomensclinic.com.au | airliewomensclinic.com.au | 100% | #3,142,891 | – | |
triadpublishing.com | triadpublishing.com | 92% | – | ||
lungcancertips.com | lungcancertips.com | 82% | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oncimmune
Complete news archive for Oncimmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oncimmune
Oncimmune was founded in 2006 and raised its 1st funding round 5 years after it was founded.
Oncimmune is headquartered in Nottingham, United Kingdom.
Geoffrey Hamilton Fairley is the CEO of Oncimmune, as recorded in our data. They have also founded this company.
Oncimmune is engaged in the development of advanced antibody biomarker discovery platforms, primarily through its proprietary ImmunoINSIGHTS engine. The company operates in the healthcare and biotechnology sectors, offering solutions for precision medicine across areas such as immuno-oncology, autoimmune diseases, and infectious diseases. Services include targeted panels, arrays, and bioinformatics for data integration. With a vast antigen library and cutting-edge technology, Oncimmune collaborates with clients to provide insights into the immune system for improved diagnostics and treatments.
Oncimmune's top competitors include Oxford Cancer Analytics and Inivata.
Oncimmune offers ImmunoINSIGHTSâ„¢, Targeted Panels & Arrays, and Bioinformatics & Data Science.
Oncimmune has made 1 acquisition, including Protagen.
Oncimmune has 5 investors. Key investors include Freenome Health, HHS, UK Research and Innovation, IPF Partners, and Genostics.
Oncimmune operates through Alden Scientific Holdings Incorporated.
Yes. Oncimmune was acquired by Freenome in May 2023.